Pfizer Global Call for Collaborators – RSV OA Research
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Monday 24th, March 2025
External Deadline: Monday 31st, March 2025
Description
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMGP CFC research program involves a publicly posted general Call for Collaborator(s) (CFC(s)) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific CFC.
Date CFC Issued: February 27, 2025
Geographic Scope: Global
Clinical Area: Infectious Disease – Respiratory Syncytial Virus (RSV)
Link to full CFC: Global Call for Collaborators – Pfizer RSV OA Research
Application Due Date: March 31, 2025
NOTE: The CyberGrants application portal will be available for application submissions starting March 14, 2025.
Specific Area of Interest: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease (LRTD) among adults and can lead to serious morbidity and mortality, especially among older adults and adults with underlying comorbidities, such as immunocomprising conditions.
The intent of this CFC is to identify investigators with research ideas who want to partner and co-develop research studies with Pfizer. Projects may also potentially involve other investigators if multiple proposals share similar objectives and methodological approaches. In these instances, Pfizer, along with the investigators, may pursue a single research study with multiple sites if all parties agree. This CFC will be a two-step process. The first step will be for investigators to submit a Letter of Intent (LOI) providing a high-level synopsis of the proposed project. In the second step, LOIs will be selected for further development into a potential research collaboration with Pfizer.
Refer to complete details in the full CFC document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Sue Lee (sue.lee@pfizer.com).